155 related articles for article (PubMed ID: 21881254)
1. A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.
Kawai Y; Tsukamoto S; Ito J; Akimoto K; Takahashi M
Chem Pharm Bull (Tokyo); 2011; 59(9):1110-6. PubMed ID: 21881254
[TBL] [Abstract][Full Text] [Related]
2. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
Qu Y; Fang M; Gao B; Chui RW; Vargas HM
J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
[TBL] [Abstract][Full Text] [Related]
3. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model.
Yao X; Anderson DL; Ross SA; Lang DG; Desai BZ; Cooper DC; Wheelan P; McIntyre MS; Bergquist ML; MacKenzie KI; Becherer JD; Hashim MA
Br J Pharmacol; 2008 Aug; 154(7):1446-56. PubMed ID: 18587422
[TBL] [Abstract][Full Text] [Related]
4. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
5. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
6. [Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
Zhou SB; Wang J; Liu H
Yao Xue Xue Bao; 2016 Oct; 51(10):1530-9. PubMed ID: 29932317
[TBL] [Abstract][Full Text] [Related]
7. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
8. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
9. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
Volberg WA; Koci BJ; Su W; Lin J; Zhou J
J Pharmacol Exp Ther; 2002 Jul; 302(1):320-7. PubMed ID: 12065733
[TBL] [Abstract][Full Text] [Related]
10. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
Curr Top Med Chem; 2008; 8(13):1140-51. PubMed ID: 18782009
[TBL] [Abstract][Full Text] [Related]
11. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
13. Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels.
Su X; Young EW; Underkofler HA; Kamp TJ; January CT; Beebe DJ
J Biomol Screen; 2011 Jan; 16(1):101-11. PubMed ID: 21131594
[TBL] [Abstract][Full Text] [Related]
14. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
15. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.
Wang S; Li Y; Wang J; Chen L; Zhang L; Yu H; Hou T
Mol Pharm; 2012 Apr; 9(4):996-1010. PubMed ID: 22380484
[TBL] [Abstract][Full Text] [Related]
16. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
Anwar-Mohamed A; Barakat KH; Bhat R; Noskov SY; Tyrrell DL; Tuszynski JA; Houghton M
Toxicol Lett; 2014 Nov; 230(3):382-92. PubMed ID: 25127758
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in computational prediction of HERG blockage.
Wang S; Li Y; Xu L; Li D; Hou T
Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
[TBL] [Abstract][Full Text] [Related]
18. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
19. Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
Hong HK; Park MH; Lee BH; Jo SH
Biochem Biophys Res Commun; 2010 Apr; 394(3):536-41. PubMed ID: 20211602
[TBL] [Abstract][Full Text] [Related]
20. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
